# Ampullary Carcinoma > Ampullary carcinoma in FMGE Surgery: early painless jaundice with fluctuation, ERCP biopsy, Whipple pancreaticoduodenectomy and prognosis. - Canonical URL: https://prepelephant.com/topics/fmge/surgery/ampullary-carcinoma-fmge - Exam / course: FMGE · Subject: Surgery - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Ampullary Carcinoma", PrepElephant, https://prepelephant.com/topics/fmge/surgery/ampullary-carcinoma-fmge ## Direct answer A bulging ampulla seen at side-viewing duodenoscopy, with a dilated common bile and pancreatic duct on CT (the "double duct sign"), in a jaundiced middle-aged patient is the classic presentation of ampullary carcinoma — a tumour whose strategic position at the confluence of bile and pancreatic ducts obstructs early, producing painless jaundice that characteristically fluctuates as the tumour necroses and sloughs, with visible blood in stool and hypochromic anaemia from surface ulceration. Because obstruction declares itself while tumours are still small, ampullary carcinoma is potentially curable far more often than pancreatic head cancer: pancreaticoduodenectomy (Whipple's operation) is the standard treatment, with endoscopic ampullectomy reserved for carefully staged benign adenomas or very early select T1 lesions. Five-year survival after resection substantially exceeds that of pancreatic carcinoma, and preoperative tissue via ERCP biopsy, plus staging CT for resectability and FAP assessment in younger patients, completes the workup. ## What you must remember - **Anatomy that makes the diagnosis:** the ampulla of Vater (hepatopancreatic ampulla formed by the common bile and main pancreatic ducts) with its sphincter of Oddi — tumours here obstruct both ducts early, giving the double duct sign. - **Clinical quartet:** painless obstructive jaundice that fluctuates, occult or visible gastrointestinal bleeding with iron-deficiency anaemia, anorexia and weight loss, and occasionally pancreatitis from pancreatic duct obstruction. - **Diagnosis:** side-viewing duodenoscopy with biopsy is the definitive diagnostic step; ERCP also allows stenting; CT assesses resectability (vascular invasion, metastasis); CA 19-9 is supportive, not diagnostic. - **Histology and precursor:** adenocarcinoma arising from intestinal-type ampullary epithelium or adenoma — the adenoma-carcinoma sequence underlies surveillance in familial adenomatous polyposis, where ampullary tumours cluster (third most common FAP site). - **Treatment standard:** pancreaticoduodenectomy with reconstruction (pancreaticojejunostomy, hepaticojejunostomy, gastrojejunostomy) — the operation and its complications are examinable in their own right. - **Ampullectomy niche:** benign adenomas and highly selected T1 lesions without ductal invasion may be treated endoscopically after staging, with pancreatic duct stenting to prevent stenosis-induced pancreatitis. - **Prognosis contrast:** resected ampullary carcinoma has markedly better five-year survival than pancreatic head adenocarcinoma — early obstruction drives early diagnosis; nodal status is the dominant prognostic factor. - **Jaundice fluctuation explanation:** tumour friability leads to central necrosis and sloughing, temporarily relieving obstruction — a favourite viva mechanism. ## How to work through a jaundiced workup A 58-year-old man reports three months of dark urine, pale stools and pruritus, during which the jaundice clearly lightened twice; he has also noticed blood streaks and has a haemoglobin of 9.6 g/dL. Liver tests show a cholestatic pattern; ultrasound reveals dilated intra- and extrahepatic ducts down to the ampulla plus a dilated pancreatic duct. Side-viewing duodenoscopy shows a fungating ampulla, and biopsy confirms adenocarcinoma; staging CT shows a resectable tumour without vascular encasment or metastases. The treatment is a Whipple pancreaticoduodenectomy — in the Indian setting often presenting late, so the surgeon's resectability assessment (portal vein and superior mesenteric artery relations, ascites, liver and peritoneal deposits via staging laparoscopy) decides resection versus biliary stenting and chemoradiation. Had the biopsy shown a benign villous adenoma in a fit patient, endoscopic snare ampullectomy with duct stents would be the answer. The two mechanisms in the story — fluctuating jaundice from necrosis, anaemia from ulceration — are the pattern-recognition hooks the exam reuses. ## Where students slip The classic confusions: ampullary carcinoma versus pancreatic head carcinoma (earlier jaundice, better prognosis, visible tumour at endoscopy versus invisible gland), and ampullary versus distal cholangiocarcinoma (both give obstructive jaundice; the ampullary tumour is visible and biopsiable). Second slip: choosing percutaneous biopsy when endoscopic biopsy through the duodenoscope is both diagnostic and safe. Third, forgetting the FAP connection — a young patient with ampullary adenoma prompts colonoscopy and family screening. ## Frequently asked questions ### Why does jaundice fluctuate in ampullary carcinoma? The friable tumour undergoes central necrosis and sloughing, intermittently relieving biliary obstruction before regrowth obstructs again. ### Which investigation gives the definitive diagnosis? Side-viewing duodenoscopy with biopsy of the visible ampullary tumour, complemented by CT for staging and resectability. ### What is the standard surgical treatment? Pancreaticoduodenectomy (Whipple's operation), removing the pancreatic head, duodenum, distal bile duct and gallbladder with gastrointestinal and biliary reconstruction. ### When is endoscopic ampullectomy acceptable? For benign adenomas and highly selected early T1 carcinomas without pancreatic duct invasion, performed with biliary and pancreatic duct stenting in experienced centres. ### Why does ampullary carcinoma carry better survival than pancreatic cancer? Its location obstructs the bile duct while tumours are small and early, so patients present at resectable, often node-negative stages.